Serotonin (5-HT) transmission appears altered in major depressive disorder +(1–+3). The serotonin transporter plays a critical role in 5-HT transmission by terminating the action of 5-HT by reuptake into presynaptic neurons +(4). Serotonin transporter binding is localized to serotonergic neurons +(5), and it can be regulated by drugs and by cellular mechanisms +(6, +7). Serotonin transporter has been implicated in the pathophysiology of major depressive disorder +(8) and is the target of most current antidepressants +(5).

Findings from postmortem, lesion, and brain imaging studies have suggested two main anatomical circuits involved in mood regulation +(9–+11). The first is a limbic-thalamic-cortical circuit that includes the amygdala, medial-dorsal nucleus of the thalamus, and ventrolateral prefrontal cortex. The second is a limbic-striatal-pallidal-thalamic-cortical circuit. Mood disorders may occur if there is a disruption in the functioning of a component of either circuit, both of which receive serotonergic innervation.

In addition to these circuits, the hippocampus and anterior cingulate also have serotonergic abnormalities in major depressive disorder. Female subjects with remitted depression have smaller hippocampal volumes +(12), and smaller hippocampal volume is negatively correlated with the duration of lifetime depression +(13) and is perhaps related to lower postmortem levels of serotonin transporter +(14). The anterior cingulate is implicated in the pathophysiology of major depressive disorder, and there are reports of lower blood flow and metabolism +(15–+18), smaller volume +(18), and lower postmortem serotonin transporter binding +(19) for this region. The dorsal and median raphe nuclei supply all the serotonergic projections to the forebrain. An in vivo single photon emission computerized tomography study demonstrated 19% lower [¹²³I]β-CIT serotonin transporter binding in the midbrain of subjects with major depressive disorder, compared with healthy subjects +(20).

We used positron emission tomography (PET) with the radiotracer [¹¹C](+)-6β-(4-methylthiophenyl)-1,2,3,5,6α,10β-hexahydropyrrolo[2,1-a]isoquinoline ([¹¹C]McN 5652) to examine serotonin transporter binding potential in brain regions that have quantifiable serotonin transporter, are implicated in the circuits proposed, and have 5-HT abnormalities—the amygdala, hippocampus, thalamus, putamen, anterior cingulate cortex, and midbrain. Healthy volunteer subjects were compared with medication-free subjects with major depressive disorder during a major depressive episode. We hypothesized that lower [¹¹C]McN 5652 binding would be found in the selected regions in subjects with major depressive disorder. [¹¹C]McN 5652 binding in the prefrontal cortex is too low to quantify reliably +(21). We also explored the relationship between [¹¹C]McN 5652 binding and previous exposure to antidepressants +(22), suicide attempt status, and clinical measures of depression severity.

Twenty-five subjects who met the DSM-IV criteria for a current major depressive episode and 43 healthy comparison subjects were included in the study. Their demographic and clinical characteristics are summarized +Table 1. Inclusion criteria for subjects with major depressive disorder were 1) age 18–65 years; 2) fulfillment of the DSM-IV criteria for major depressive episode; 3) absence of any psychotropic medication use for at least 2 weeks before the PET scan (6 weeks for fluoxetine, 4 weeks for oral neuroleptics), except for benzodiazepines, which were discontinued 3 days before the scan; 4) no current or lifetime history of alcohol or other drug abuse or dependence; 5) absence of lifetime exposure to 3,4-methylenedioxymethamphetamine; 6) absence of significant current medical conditions; 7) absence of pregnancy; and 8) capacity to provide informed consent. The inclusion criteria for the comparison subjects were similar. In addition, the comparison subjects were required to have no psychiatric history and no history of a mood or psychotic disorder in their first-degree relatives. All subjects gave written informed consent after explanation of the study. The Beck Depression Inventory (BDI) +(23), Hamilton Depression Rating Scale (HAM-D) +(24), and Global Assessment Scale (GAS) +(25) were used to assess subjective and objective depression severity and functional impairment, respectively.

Seven depressed subjects met the criteria for melancholia, four were experiencing their first episode of major depression, and three had too many lifetime episodes to count reliably. Nine depressed subjects had made suicide attempts (mean=1.9 attempts, SD=1.1, range=1–4). Comorbid disorders included posttraumatic stress disorder (N=4), panic disorder (N=7), dysthymia (N=5), social phobia (N=4), generalized anxiety disorder (N=2), binge eating disorder (N=1), and simple phobia (N=1). Twelve subjects had never received antidepressant medications. The mean medication-free interval (excluding benzodiazepines) in the remaining subjects was 26.5 days (SD=13.2, median=21, range=14–58). The subjects who were not medication naive had received medication between 14 and 30 days before the study and had shown no clinical response; they agreed to have their medications tapered and discontinued for the study.

[¹¹C]McN 5652 was produced as previously described +(26). The injected radioactivity of [¹¹C]McN 5652 differed between the comparison subjects (mean=11.9 mCi, SD=4.3) and the subjects with major depressive disorder (mean=14.3 mCi, SD=3.9) (t=–2.29, df=66, p<0.03), but the injected mass did not differ between groups (comparison subjects: mean=82.2 μmol, SD=62.1; subjects with major depressive disorder: mean=107.8 μmol, SD=156.6) (t=–0.95, df=66, p=0.35).

PET and magnetic resonance imaging data acquisition, analysis, and measurement of arterial input indices were previously described +(21). After a 10-minute transmission scan, [¹¹C]McN 5652 was injected intravenously, and emission data were acquired for 130 minutes. After radiotracer injection, 12 arterial samples were collected at 10-second intervals over 2 minutes, the next six samples were collected at 20-second intervals over 2 minutes, and the remaining 13 samples were collected at longer intervals, for a total of 31 samples. The first 18 samples were collected with an automated sampling system, and the remaining samples were manually drawn. Six samples (collected at 2, 20, 50, 80, 110, and 130 minutes) were further processed by high-pressure liquid chromatography to measure the fraction of plasma activity representing unmetabolized parent compound. Regions of interest were traced by using brain atlases +(27, +28) and published reports +(29, +30). A neuroanatomist (V.A.) verified the regions of interest. Derivation of [¹¹C]McN 5652 regional distribution volume (V_T) was performed with likelihood estimation in a graphical approach +(31–+33). V_T is the sum of the specific (V₃) and nondisplaceable (free plus nonspecific binding) (V₂) distribution volumes. Binding potential (BP′) was calculated as follows: V_T – V₂, equivalent to f₁B_max/K_d, where f1 is the free concentration of the radiotracer in plasma, Bmax is the maximum number of binding sites, and Kd is the dissociation constant. V₂ was measured in a 12.1-cm³ (± 1.5 cm³) sample of the cerebellum.

Data were analyzed by using linear mixed-effects models, with region and diagnostic group as fixed effects and subject as the random effect. To stabilize variance and satisfy modeling assumptions, natural log-transformed data were used in the analysis after a quantity was added to all measures to ensure positive values. The reported p values were not adjusted for multiple comparisons.

The group with major depressive episode included a greater proportion of female subjects, relative to the comparison group (+Table 1), but no effect of sex was found in the mixed model (F=0.26, df=1, 63, p=0.62). Across the six regions of interest, BP′ differed significantly by diagnostic group (F=2.82, df=5, 330, p<0.02). In post hoc tests examining the effect of diagnostic group on BP′ in each region in the mixed model, significantly lower BP′ was found in the amygdala (t=–2.29, df=329, p<0.03) and midbrain (t=–2.22, df=329, p<0.03) in the subjects with major depressive disorder, relative to the comparison subjects.

Selective serotonin reuptake inhibitors are cleared from the brain about 2 weeks after discontinuation +(34), and therefore, residual drug should not occupy the serotonin transporters after that period. However, medication may have long-term effects such as suppression of gene expression +(35), although this possibility is controversial +(22, +36). To rule out effects of prior treatment with antidepressants, data for 13 subjects with major depressive disorder who had been medication free for at least 14 days were compared to data for 12 subjects who had never received antidepressants and to data for the comparison subjects. We found a significant effect of region and medication status (F=2.23, df=10, 325, p<0.02) (+Figure 1). Post hoc testing revealed significantly lower BP′ in the amygdala (t=–2.93, df=323, p=0.003) (+Figure 2) and midbrain (t=–2.37, df=323, p<0.02) for the antidepressant-naive subjects, relative to the comparison subjects. When the data for the comparison subjects were excluded from the analysis, there was no difference in BP′ between the antidepressant-naive and recently medicated groups across all brain regions (F=0.71, df=1, 23, p=0.41), although the interaction of region and medication status approached significance (F=2.24, df=5, 115, p=0.055). The 12 antidepressant-naive subjects did not differ from the 13 recently treated subjects in demographic and clinical characteristics, except that the recently treated subjects were more likely to be inpatients (+Table 2). No correlation was found between the time since discontinuation of antidepressants and BP′ in any region of interest (data not shown), although the previously medicated subjects had a median time of only 21 days since discontinuation of antidepressants.

A group-by-region interaction was found in the comparison of BP′ in the subjects with major depressive disorder who had a history of at least one suicide attempt, the subjects with major depressive disorder who had never attempted suicide, and the comparison subjects (F=1.12, df=10, 325, p<0.05). Post hoc analysis revealed that this difference was due to differences in BP′ in the amygdala and midbrain between the comparison subjects and the subjects with major depressive disorder who had never attempted suicide. No differences in BP′ were found between the suicide attempters and nonattempters or between the attempters and the comparison subjects (data not shown).

No significant correlation was found between the BP′ in any region of interest and the measures of depression severity, including the BDI and HAM-D scores, age at first major depressive episode, number of previous major depressive episodes, or length of current major depressive episode.

We found lower midbrain and amygdala [¹¹C]McN 5652 BP′ in major depressive disorder and found that this effect was more pronounced in depressed subjects who had never received antidepressants. There was no correlation between BP′ and depression severity. There was no difference in BP′ between the major depressive disorder subjects with a history of suicide attempt and those with no history of suicide attempt.

Our finding of a 20% lower BP′ in the midbrain in subjects with major depressive disorder, compared to healthy volunteers, is in agreement with that of Malison et al. +(20), who found a 19% lower [¹²³I]β-CIT binding in subjects with major depressive disorder, but is at odds with the findings of Ichimiya et al. +(37), who reported no difference in midbrain [¹¹C]McN 5652 V₃′′ (V₃′′ is defined later in the Discussion section) and higher V₃′′ in the thalamus of depressed subjects. It should be noted that the study by Ichimiya et al. 1) included euthymic subjects; 2) used data from 90-minute scans; 3) used age as a covariate (we could detect no age-related changes in BP′ in the midbrain); 4) used the graphical method of Logan, which is reported to have noise-dependent bias +(38); and 5) had a smaller number of depressed subjects (N=13). Our data are also consistent with the results of a previous PET study with the transporter radioligand [¹¹C] N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine ([¹¹C]DASB) in which no difference in striatal V₃′′ was found between depressed subjects and healthy comparison subjects +(39). We found a 20% lower BP′ in the amygdala in subjects with major depressive disorder, compared to healthy subjects; to our knowledge, this finding has not been reported previously.

We interpret the lower [¹¹C]McN 5652 BP′ (f₁B_max/K_d) in the subjects with major depressive disorder to reflect lower B_max, or lower total number of available serotonin transporter binding sites. Several outcome measures are used in PET studies, including BP (B_max/K_d=V_T – V₂/f₁), BP′ (f₁B_max/K_d=V_T – V₂), and V₃′′ (f₂B_max/K_d=BP′/V₂), where VT is the total volume of distribution in an region of interest, V2 is a measure of the free and nonspecifically bound tracer, f1 is the free concentration of the radiotracer in plasma, and f2 is the free concentration of the radiotracer in the cerebrospinal fluid. Ideally we would measure BP, but f₁ is not measurable with [¹¹C]McN 5652. Our findings were similar when either of the outcome measures that can be determined with [¹¹C]McN 5652 was used, i.e., the principal region-by-diagnosis interaction was significant with BP′ or V₃′′ (p<0.05), and the interaction of region and prior antidepressant medication status was significant with V₃′′ (p<0.03). We believe the lower BP′ in major depressive disorder is not a consequence of f₁, because our findings are consistent with postmortem findings, where f₁ is not a factor, and because changes in f₁ would result in global differences, not regionally specific ones. Finally, postmortem studies suggested that lower levels of serotonin transporter in subjects with major depressive disorder are not due to changes in receptor affinity (1/_d) +(14). It is unlikely that the lower BP′ in major depressive disorder could be a consequence of higher synaptic levels of 5-HT, because of the hypothesized serotonin abnormality in depression. Moreover, in postmortem studies that included a preincubation period to promote catabolism and a washout of endogenous 5-HT before adding ligand in vitro, lower serotonin transporter binding was found in major depressive disorder +(40–+42). These findings appear to rule out elevated intrasynaptic levels of 5-HT as an explanation. Therefore, our finding of lower serotonin transporter BP′ in major depressive disorder is likely a result of lower serotonin transporter B_max, i.e., fewer serotonin transporters.

There are several possible explanations for the lower serotonin transporter B_max in major depressive disorder. Lower levels of synaptic 5-HT could facilitate serotonin transporter internalization +(6); there could be fewer 5-HT neurons or neuronal processes or decreased expression of serotonin transporter per terminal; or a combination of these factors could be operating. Lower levels of synaptic 5-HT in the raphe nuclei could be related to the presence of the C(-1019)G polymorphism of the promoter region of the 5-HT_1A gene that has been shown to be overrepresented in patients with major depressive disorder +(43). The C(-1019) allele is part of a 26-base pair imperfect palindrome with less affinity for the nuclear deformed epidermal autoregulatory factor transcriptional repressor, and this lower level of affinity could potentially result in a higher level of expression of the 5-HT_1A protein in the raphe nuclei. Because the raphe nuclei 5-HT_1A receptors are inhibitory, higher levels of 5-HT_1A in the raphe nuclei would result in lower levels of 5-HT release and possible down-regulation of serotonin transporter. Alternatively, lower levels of synaptic 5-HT could be related to having a variant of the tryptophan hydroxylase-2 gene, which has less catalytic activity and is present in 10% of subjects with major depressive disorder +(44, +45). Down-regulation of serotonin transporter should be accompanied by reduced mRNA for serotonin transporter. Our previous autoradiography studies suggested that the number of neurons that express serotonin transporter mRNA is reduced by 54% in subjects with major depressive disorder who commit suicide +(42), although the number of 5-HT-producing neurons did not appear to be decreased +(46).

We hypothesized that a lower level of serotonin transporter in all six regions of interest was necessary for the expression of major depressive disorder, but we found differences in serotonin transporter binding potential only in the midbrain and amygdala. These findings can be interpreted in several ways. First, it is possible that the midbrain and amygdala are the crucial structures in the pathophysiology of depression, and serotonin transporter abnormalities in these regions are sufficient to result in major depressive disorder. Second, the abnormalities in the other regions of interest may not be specific to serotonin transporter but perhaps may involve other measures of serotonergic function. Third, the lower level of serotonin transporter BP′ in the midbrain and amygdala may be secondary to as yet undetermined primary pathological process(es). Finally, the PET ligand we used may not be sensitive enough to detect serotonin transporter abnormalities in the other regions.

For the differences in serotonin transporter BP′ to be limited to the midbrain and amygdala, the abnormality may be confined to a subpopulation of serotonin-transporter-expressing 5-HT neurons within the dorsal raphe nuclei. Less 5-HT input to the amygdala, as suggested by the finding of lower serotonin transporter BP′, may result in increased amygdala activity +(47), as serotonin enhances inhibition in the amygdala, presumably through activation of γ-aminobutyric-acid-ergic interneurons +(48). Serotonergic projections to the amygdala are implicated in anxiety disorders as well +(49). Previous research has suggested an association between hyperactivity in the amygdala and a greater likelihood that sensory or social stimuli are perceived or remembered as emotionally arousing or aversive +(50); thus, hyperactivity in the amygdala may contribute to the relationship between adverse childhood experiences and adult mood disorders.

Received June 2, 2004; revisions received Jan. 11 and March 1, 2005; accepted April 13, 2005. From the Departments of Psychiatry and Radiology, Columbia University College of Physicians and Surgeons, New York; the Departments of Neuroscience and Analytic Psychopharmacology, New York State Psychiatric Institute; and the Department of Biostatistics, Columbia University School of Public Health, New York. Address correspondence and reprint requests to Dr. Parsey, Department of Neuroscience, New York State Psychiatric Institute, 1051 Riverside Dr., Box 42, New York, NY 10032; rparsey@neuron.cpmc.columbia.edu (e-mail). This article is the second of two on serotonin transporters in the human brain in this issue of the Journal. The first article immediately precedes this one. Supported by NIMH grants P30 MH-46745, MH-40695, MH-40210, and MH-62185, the National Alliance for Research on Schizophrenia and Depression, and the American Foundation for Suicide Prevention. The authors thank the staff of the Brain Imaging Division, Kreitchman PET Center, and Sarina M. Rodrigues, Ph.D., for their assistance.